Article Details

New 5-Year KEYNOTE-024 Data Show Pembrolizumab Continues to Prolong OS in NSCLC

Retrieved on: 2021-05-11 15:56:15

Tags for this article:

Click the tags to see associated articles and topics

New 5-Year KEYNOTE-024 Data Show Pembrolizumab Continues to Prolong OS in NSCLC. View article details on hiswai:

Excerpt

The findings add new evidence to the case for the PD-1–targeting monoclonal antibodies in the first-line setting for metastatic NSCLC. The report was ...

Article found on: www.cancernetwork.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo